Lipoprotein(a) and diabetes mellitus: insights from epidemiological and genetic studies
Authors:
Jana Beňová Becherová; Lukáš Zlatohlávek
Authors‘ workplace:
Centrum preventivní kardiologie, III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in:
AtheroRev 2024; 9(3): 130-134
Category:
Reviews
Overview
This article synthesizes findings from various epidemiological and genetic studies to elucidate the complex interactions between lipoprotein(a)/Lp(a) levels, Lp(a) isoform size, and the risk of diabetes mellitus. Understanding these associations is essential for developing targeted interventions to manage and potentially mitigate the cardiovascular risks associated with this condition. Epidemiological studies indicate an inverse relationship between Lp(a) concentrations and the risk of developing type 2 diabetes mellitus (T2DM), highlighting the potential of Lp(a) as a marker for identifying individuals at high risk. Genetic studies, particularly those examining kringle IV type 2 (KIV-2) variants, suggest that larger isoforms associated with lower Lp(a) levels may increase the risk of T2DM. Pathophysiological mechanisms such as atherogenic properties, pro-inflammatory effects, insulin resistance, and endothelial dysfunction link Lp(a) with both cardiovascular and metabolic risks in diabetic patients. Monitoring Lp(a) levels could be crucial for managing cardiovascular risks in diabetics, underscoring the need for further research to clarify these relationships and develop effective clinical strategies.
Keywords:
lipoprotein(a) – diabetes mellitus – epidemiological studies – genetic studies
Sources
Paige E, Masconi LM, Tsimikas S et al. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol 2017; 16:38. Dostupné z DOI: <https://doi.org/10.1186/s12933–017–0520-z>.
Fu Q, Hu L, Xu Y et al. High lipoprotein(a) concentrations are associated with lower type 2 diabetes risk in the Chinese Han population: a large retrospective cohort study. Lipids Health Dis 2021; 20:76. Dostupné z DOI: <https://doi.org/10.1186/s12944–021–01504-x>.
Mu-Han-Ha-Li D, Zhai T, Ling Y et al. LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk. J Lipid Res 2018; 59(5): 884–891. Dostupné z DOI: <https://doi. 10.1194/jlr.P082792>.
Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol 2013; 1(3): 220–227. Dostupné z DOI: <https://doi.org/10.1016/S2213–8587(13)70064–0>.
Nakamura H, Kataoka Y, Nicholls SJ et al. Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry. Atherosclerosis 2022; 349: 183–189. Dostupné z DOI: <https://doi 10.1016/j.atherosclerosis.2022.03.033>.
Amor AJ, Castelblanco E, Hernández M et al. Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles. Cardiovasc Diabetol 2020; 19(1): 126. Dostupné z DOI: <https://doi.org/10.1186/s12933–020–01099–0>.
Paige E, Masconi KL, Tsimikas S et al. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol 2017; 16(1): 38. Dostupné z DOI: <https://doi.org/10.1186/s12933–017–0520-z>.
Mora S, Kamstrup PR, Rifai N et al. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010; 56(8): 1252–1260. Dostupné z DOI: <http://dx.doi.org/10.1373/clinchem.2010.146779>.
Peela JR, Latiwesh OB, Elshaari F et al. Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients. Cureus 2018; 10(7): e3030. Dostupné z DOI: <http://dx.doi.org/10.7759/cureus.3030>.
Hernández C, Francisco G, Chacón P et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Mortality in Type 2 Diabetic Patients: A 10-year follow-up study. Diabetes Care 2005; 28(4): 931–933. Dostupné z DOI: <https://doi.org/10.2337/diacare.28.4.931>.
Shah NP, Wang Q, Wolski KE et al. The Role of Lipoprotein(a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes Care 2020; 43(2): e22-e24. Dostupné z DOI: <http://dx.doi.org/https://doi.org/10.2337/dc19–1117>.
Buchmann N, Scholz M, Lill CM et al. Association between lipoprotein(a) level and type 2 diabetes: no evidence for a causal role of lipoprotein(a) and insulin. Acta Diabetol 2017; 54(11): 1031–1038. Dostupné z DOI: <http://dx.doi.org/10.1007/s00592–017–1036–4>.
Littmann K, Wodaje T, Alvarsson M et al. The Association of Lipoprotein(a) Plasma Levels with Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients with Type 1 Diabetes. Diabetes Care 2020; 43(8): 1851–1858. Dostupné z DOI: <https://doi.org/10.2337/dc19–1398>.
Lamina C, Ward NC. Lipoprotein(a) and diabetes mellitus. Atherosclerosis 2022; 349: 63–71. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2022.04.016>.
Robbins DC, Howard BV. Lipoprotein(a) and Diabetes. Diabetes Care 1991; 14(4): 347–349. Dostupné z DOI: <https://doi.org/10.2337/diacare.14.4.347>.
Zlatohlávek L. Update role Lp(a) při určení kardiovaskulárního rizika a možnosti jeho ovlivnění. Kardiol Rev Int Med 2019; 21(2): 68–69.
Haffner SM. Lipoprotein(a) and Diabetes: An update. Diabetes Care 1993; 16(5): 835–840. Dostupné z DOI: <https://doi.org/10.2337/diacare.16.5.835>.
Kronenberg F, Mora S, Stroes E et al. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis 2023; 374: 107–120. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2023.04.012>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2024 Issue 3
Most read in this issue
- Inflammation in atherosclerosis as a potential therapeutic target
- Eggs: nutritional and health importance for the general population and patients with statin therapy
- 28th Congress on Atherosclerosis, 12th–14th December 2024, Brno
- Statin intolerance in questions and answers